Projects per year
Personal profile
Personal profile
Dr. Aparna Kamat is the director of the Division of Gynecologic Oncology for Houston Methodist and is currently the section leader for the Gynecologic Oncology service line. After completing medical training in India, Dr. Kamat completed her residency in OB/GYN at West Virginia University where she served as chief resident.
She completed her fellowship training in Gynecologic Oncology at the MD Anderson Cancer Center. During her fellowship, she received multiple awards for her research in ovarian cancer and endometrial cancer including the Virginia K. Pierce award and the Asche Murray fellowship. She also received the prestigious BIRCWH award from the N.I.H. for her research in biomarkers for ovarian cancer. Dr. Kamat currently is the principle investigator for the Gynecologic Oncology Group Clinical Trials Program at Houston Methodist and offers several state-of-the-art clinical trials for patients with gynecologic malignancies.
Her areas of expertise are robotic and minimally invasive surgical options for women with gynecologic cancers and complex pelvic disease. Her other clinical interests include hereditary risk assessment and treatment of gynecologic malignancies.
Research Area Keywords
- Cancer
Free-text keywords
- Gynecologic cancer
- Pelvic disease
- Hereditary risk assessment
- Minimally invasive surgery
- Gynecologic malignancy
Fingerprint
Dive into the research topics where Aparna A. Kamat is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
GOG-3044 LAE002INT2001
Kamat, A. A., Alaniz, A., Singh, M., Suri, A. & Zaid, T.
4/16/21 → …
Project: Clinical Trial
-
An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-ResistantOvarian Cancer
Kamat, A. A., Alaniz, A., Darcourt, J., Singh, M., Suri, A. & Zaid, T.
3/15/21 → 3/14/46
Project: Non Profit
-
A phase III, multicenter, randomized, study of atezolizumab/placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
Kamat, A. A., Alaniz, A., Bernicker, E. H., Darcourt, J., Heyne, K., Singh, M., Suri, A. & Zaid, T.
3/13/18 → 3/12/43
Project: Non Profit
-
Ovarian Cancer
Hanafy, A. K., Morani, A. C., Jensen, C. T., Kamat, A., Eifel, P. J. & Bhosale, P. R., Jan 1 2022, Oncologic Imaging: A Multidisciplinary Approach. Elsevier, p. 452-475 24 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter
-
The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine
O’Connell, C., VandenHeuvel, S., Kamat, A., Raghavan, S. & Godin, B., Sep 2022, In: International journal of molecular sciences. 23, 17, 9981.Research output: Contribution to journal › Review article › peer-review
Open Access -
Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma (Nature Medicine, (2006), 12, 8, (939-944), 10.1038/nm1447)
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., Merritt, W. M., Lin, Y. G., Mangala, L. S., Kim, T. J., Coleman, R. L., Landen, C. N., Li, Y., Felix, E., Sanguino, A. M., Newman, R. A., & 7 others, Dec 2021, In: Nature Medicine. 27, 12, p. 2246 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access1 Scopus citations -
Erratum: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer (Clinical Cancer Research (2006) 12 (1707-1714) DOI: 10.1158/1078-0432.CCR-05-2338)
Kamat, A. A., Fletcher, M., Gruman, L. M., Mueller, P., Lopez, A., Landen, C. N., Han, L., Gershenson, D. M. & Sood, A. K., Aug 1 2021, In: Clinical Cancer Research. 27, 15, p. 4455 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Erratum: Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy (Clin Cancer Res (2019) 12(4916–4924)Doi:10.1158/1078-0432.CCR-06-0021)
Halder, J., Kamat, A. A., Landen, C. N., Han, L. Y., Lutgendorf, S. K., Lin, Y. G., Merritt, W. M., Jennings, N. B., Chavez-Reyes, A., Coleman, R. L., Gershenson, D. M., Schmandt, R., Cole, S. W., Lopez-Berestein, G. & Sood, A. K., 2019, In: Clinical Cancer Research. 25, 10, p. 3194 1 p.Research output: Contribution to journal › Comment/debate › peer-review
1 Scopus citations